Cagrilintide is a synthetic amylin analog developed for investigational use in metabolic research. It is structurally modified to enhance receptor affinity and extend half-life, making it suitable for studies involving energy balance, satiety signaling, and glucose regulation.

Researchers have explored cagrilintide in preclinical and clinical settings for its ptential role in modulating appetite, delaying gastric emptying, and influencing postprandial glucose dynamics.